Acute mesenteric ischemia: updated guidelines of the World Society of Emergency Surgery
Executive Summary
Acute Mesenteric Ischemia (AMI) is a group of life-threatening diseases characterized by the sudden interruption of blood supply to the small intestine. Although rare, accounting for only 0.09–0.2% of acute surgical admissions, AMI carries a consistently high mortality rate of approximately 50%, which can rise to 80% without prompt intervention. Early diagnosis and timely surgical intervention are the cornerstones of effective treatment.
The World Society of Emergency Surgery (WSES) guidelines emphasize that a high index of clinical suspicion is paramount. The classic presentation is severe abdominal pain that is disproportionate to the findings on physical examination; this scenario should be treated as AMI until proven otherwise. Once suspected, Computed Tomography Angiography (CTA) is the definitive diagnostic tool and should be performed immediately, even in the presence of renal failure, as the risks of delayed diagnosis are far greater.
Management is a multi-faceted and urgent process. It begins with immediate fluid resuscitation, correction of electrolyte imbalances, and administration of broad-spectrum antibiotics and unfractionated heparin. For patients presenting with peritonitis, a sign of irreversible bowel necrosis, prompt laparotomy is mandatory. The goals of surgery are to re-establish blood flow, resect non-viable bowel, and preserve all viable intestines. Damage Control Surgery (DCS) with a planned "second-look" laparotomy within 48 hours is an essential strategy, particularly in critically ill patients, to reassess bowel viability after initial resuscitation and revascularization.
The specific etiology of AMI—mesenteric arterial embolism (50%), arterial thrombosis (15-25%), non-occlusive mesenteric ischemia (NOMI, 20%), or mesenteric venous thrombosis (MVT, 5-15%)—guides the treatment strategy. While open surgery remains the standard for peritonitis, endovascular procedures may have a role in select cases of partial occlusion without bowel infarction. Management of NOMI focuses on correcting the underlying low-flow state, while MVT can often be managed with anticoagulation alone if there are no signs of peritonitis.
I. Overview of Acute Mesenteric Ischemia
Acute Mesenteric Ischemia (AMI) is defined as the sudden interruption of blood supply to a portion of the small intestine, a process that leads to ischemia, cellular damage, and ultimately, intestinal necrosis and patient death if not treated.
Incidence: AMI is an uncommon cause of abdominal pain, with a low incidence estimated at 0.09% to 0.2% of all acute admissions to emergency departments.
Mortality: Despite advances in medicine, mortality remains high, consistently reported in the range of 50% to 80%. Delay in diagnosis is the dominant factor contributing to these high rates.
Core Principles: The foundations of modern treatment are early diagnosis and timely surgical intervention. The guidelines aim to provide practical recommendations to improve outcomes by focusing on prompt diagnosis, revascularization potential, resection of necrotic intestine, and the use of damage control techniques.
II. Pathophysiology and Etiology
AMI can be classified as occlusive or non-occlusive, with four primary etiologies. A careful patient history is crucial, as distinct clinical scenarios are associated with each form.
III. Clinical Diagnosis and Evaluation
Early diagnosis relies on maintaining a high level of clinical suspicion, as initial signs can be subtle.
Core Diagnostic Principle
"Severe abdominal pain out of proportion to physical examination findings should be assumed to be AMI until disproven." (Recommendation 1B) The classic presentation of excruciating pain with an unrevealing abdominal exam is highly suggestive of early AMI. The presence of peritonitis signifies likely irreversible intestinal ischemia and bowel necrosis.
Clinical Presentation
Common Symptoms: In one study, 95% of patients presented with abdominal pain, 44% with nausea, 35% with vomiting, 35% with diarrhea, and 16% with blood per rectum.
Classic Triad: Approximately one-third of patients present with the triad of abdominal pain, fever, and hemoccult-positive stools.
Laboratory and Conventional Imaging
Laboratory Studies (Recommendation 1B): No laboratory study is sufficiently accurate to definitively diagnose AMI. However, abnormalities can corroborate clinical suspicion:
Leukocyte Count: Abnormally elevated in over 90% of patients.
Lactate: Metabolic acidosis with an elevated lactate level is the second most common finding (88%). A level >2 mmol/l was associated with irreversible intestinal ischemia (Hazard Ratio: 4.1). However, lactate alone is not reliable for differentiation.
D-dimer: A normal D-dimer helps to exclude intestinal ischemia. A D-dimer >0.9 mg/L has been reported to have a specificity of 82% and sensitivity of 60%.
Plain X-ray Films (Recommendation 1B): These have limited diagnostic value, especially in early stages. A negative radiograph does not exclude AMI. Findings only become positive when bowel infarction has developed, such as free intraperitoneal air from perforation.
IV. Computed Tomography Angiography (CTA): The Diagnostic Standard
"Computed tomography angiography (CTA) should be performed as soon as possible for any patient with suspicion for AMI." (Recommendation 1A)
The multi-detector CTA (MDCT) has supplanted formal angiography as the diagnostic study of choice, as it is essential for early diagnosis.
Diagnostic Accuracy: MDCT has demonstrated high accuracy, with a sensitivity of 93%, specificity of 100%, and positive and negative predictive values of 100% and 94%, respectively. One study found MDCT correctly diagnosed AMI in 96.4% of patients.
Technique: A comprehensive biphasic CTA protocol is recommended:
Pre-contrast scans: To detect vascular calcification and thrombus.
Arterial and venous phases: To demonstrate thrombus, abnormal bowel wall enhancement, and infarction of other organs.
Multi-planar reconstructions (MPR): To assess the origin of mesenteric arteries. 3D reconstruction can also be helpful.
Key Findings: CTA can identify the cause (e.g., thrombus in the SMA or SMV) and signs of irreversible ischemia, including intestinal dilatation, lack of visceral enhancement, pneumatosis intestinalis (gas in the bowel wall), and portal venous gas.
Renal Failure: CTA should be performed despite the presence of renal failure, as the consequences of a missed or delayed diagnosis are far more detrimental than the risk of contrast-induced nephropathy.
V. Initial Management and Resuscitation
Once AMI is diagnosed, management must commence immediately to optimize patient physiology before and during intervention.
Fluid Resuscitation (Recommendation 1B): Begin immediate fluid resuscitation with crystalloids and blood products to enhance visceral perfusion and prevent cardiovascular collapse upon induction of anesthesia. Early hemodynamic monitoring is essential to guide therapy and avoid fluid overload, which can worsen bowel perfusion and lead to abdominal compartment syndrome.
Pharmacological Support: Vasopressors should be used with caution. Agents like dobutamine, low-dose dopamine, and milrinone are preferred as they have been shown to have less negative impact on mesenteric blood flow.
Antibiotics and Anticoagulation (Recommendation 1B):
Antibiotics: Administer broad-spectrum antibiotics immediately due to the high risk of bacterial translocation across the compromised mucosal barrier.
Anticoagulation: Unless contraindicated, patients should be anticoagulated with a continuous infusion of intravenous unfractionated heparin.
VI. Surgical and Interventional Strategies
The definitive management of AMI involves restoring blood flow and dealing with its consequences on the intestine.
Laparotomy and Revascularization
Prompt Laparotomy (Recommendation 1A): Patients with overt peritonitis require prompt laparotomy without delay. The goals of surgery are to re-establish blood supply, resect non-viable bowel, and preserve all viable bowel.
Open Revascularization: Techniques depend on the pathology.
Embolectomy: Definitive treatment for SMA emboli.
Bypass Procedure: Required for SMA thrombosis at the aortic origin, often involving a retrograde bypass from the iliac artery to the distal SMA.
Endovascular Revascularization
Role and Limitations (Recommendation 1C): Endovascular techniques may have a role in cases with partial arterial occlusion and no clinical or imaging evidence of advanced bowel ischemia or infarction. Contraindications include recent surgery, trauma, and uncontrolled hypertension.
Outcomes: In a retrospective series, endovascular treatment was performed in 24% of patients, with a technical success rate of 87% and lower in-hospital mortality compared to open procedures (25% vs. 40%). However, these patients were selected as not requiring emergent open intervention.
Adjuncts: In cases managed with an endovascular-first approach, laparoscopy may be a reasonable addition to assess bowel viability.
Damage Control Surgery (DCS)
Core Strategy (Recommendation 1B): DCS is an essential adjunct and the surgical modality of choice for critically ill patients with AMI. It addresses the physiological derangements of acidosis, hypothermia, and coagulopathy.
Planned Re-laparotomy: A planned "second look" operation within 48 hours is a critical part of AMI management. This allows for reassessment of bowel that was of questionable viability at the initial operation, which may improve after blood flow is restored and the patient is stabilized. Decisions regarding further resection, anastomosis, or stoma creation are made at the second look.
Open Abdomen: The abdomen is often left open and managed with negative pressure wound therapy to reduce the risk of abdominal compartment syndrome.
VII. Management of Specific Subtypes
Non-Occlusive Mesenteric Ischemia (NOMI)
Suspicion (Recommendation 1B): NOMI should be suspected in critically ill patients requiring vasopressor support who develop abdominal pain, distension, or evidence of multi-organ dysfunction.
Management (Recommendation 1B): The primary focus is to correct the underlying cause, including optimizing cardiac output and eliminating vasopressors. Catheter-directed infusion of vasodilators like papaverine may be used. Surgical resection of infarcted bowel is required if peritonitis develops. Mortality remains very high (50-85%).
Mesenteric Venous Thrombosis (MVT)
Management (Recommendation 1B): MVT can often be successfully treated with a continuous infusion of unfractionated heparin, provided there are no signs of peritonitis. When surgery is required, the goal is to resect only obviously necrotic bowel and utilize damage control techniques, as anticoagulation may improve the viability of borderline bowel over 24-48 hours. A second-look laparotomy is mandatory in patients with extensive bowel involvement.
VIII. Recommendations and Ethical Considerations
The finding of massive, unsalvageable gut necrosis presents a profound clinical and ethical challenge.
Philosophical Decision (Recommendation 1C): When faced with extensive infarction, the surgeon must carefully assess the patient's underlying comorbidities and advanced directives. Resecting the entire involved bowel results in short bowel syndrome, a state that may not be preferable for elderly or infirm patients who cannot tolerate long-term parenteral nutrition. A discussion with the patient and family is warranted to establish an agreeable plan.
